Intel, Lenovo and Diaceutics are improving the existing diagnosis process with a solution that unlocks the capabilities of AI to process meaningful data and allow health care providers to deliver the right medicine at the right time to patients.

Lenovo’s enterprise workstations powered by Intel Xeon Scalable processors will provide the computing power necessary to process Diaceutics’ vast proprietary database of patient testing data. Doctors and health care providers will be able to deploy AI-based techniques to large data sets to generate accurate, real-time insight from diagnostic testing.

By integrating testing results with treatment paths, pharmaceutical companies can develop a targeted plan for correctly treating diseases. Initial trials will target treatments for cancer patients, where Diaceutics has a robust data set, with intent to expand to other diseases in the future.